Caricamento...
Severe FGF23-based hypophosphataemic osteomalacia due to ferric carboxymaltose administration
Ferric carboxymaltose (FCM) is a novel iron formulation increasingly prescribed due to its effectiveness and fast infusion time. FCM administration can cause an asymptomatic hypophosphataemia secondary to fibroblast growth factor 23 (FGF23) dysregulation. In patients with chronic iron needs, however...
Salvato in:
| Pubblicato in: | BMJ Case Rep |
|---|---|
| Autori principali: | , , , |
| Natura: | Artigo |
| Lingua: | Inglês |
| Pubblicazione: |
BMJ Publishing Group
2018
|
| Soggetti: | |
| Accesso online: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5775795/ https://ncbi.nlm.nih.gov/pubmed/29298794 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1136/bcr-2017-222851 |
| Tags: |
Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !
|